Moreover, utilizing the investigative BRD4-targeted PROTAC MZ-1 in combination with genetic or pharmacologic JUNB targeting approaches, we emphasize the opportunity to employ MYC and JUNB dual-targeting treatment strategies in MM, as an exciting approach to further improve patient outcome. This evidence concerns the gene BRD4 and Miyoshi myopathy.